These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 30569379

  • 21. Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.
    Homann A, Röckendorf N, Kromminga A, Frey A, Platts-Mills TA, Jappe U.
    Theranostics; 2017; 7(19):4699-4709. PubMed ID: 29187897
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
    Jentzer A, Berger AE, Labetoulle R, Haccourt A, Roblin X, Paul S.
    Ther Drug Monit; 2018 Dec; 40(6):749-753. PubMed ID: 30439790
    [Abstract] [Full Text] [Related]

  • 23. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.
    Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
    [Abstract] [Full Text] [Related]

  • 24. A review of six methods for monitoring infliximab concentrations and antibodies to infliximab
.
    Cao F, Cao H, Cao X.
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):571-580. PubMed ID: 28513424
    [Abstract] [Full Text] [Related]

  • 25. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
    Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, Gils A.
    Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
    [Abstract] [Full Text] [Related]

  • 26. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [Abstract] [Full Text] [Related]

  • 27. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
    Jukic T, Drobne D, Pusavec S, Ihan A, Stubljar D, Starc A.
    Med Sci Monit; 2023 Feb 18; 29():e939084. PubMed ID: 36807319
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
    Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F, Portuguese IBD Study Group (GEDII).
    Aliment Pharmacol Ther; 2016 Oct 18; 44(7):684-92. PubMed ID: 27507790
    [Abstract] [Full Text] [Related]

  • 31. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
    Hock BD, McKenzie JL, Goddard L, Smith SM, McEntyre CJ, Keating PE.
    Ther Drug Monit; 2018 Dec 18; 40(6):705-715. PubMed ID: 30439789
    [Abstract] [Full Text] [Related]

  • 32. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C.
    Dig Dis Sci; 2018 Jun 18; 63(6):1583-1591. PubMed ID: 29564674
    [Abstract] [Full Text] [Related]

  • 33. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
    Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ.
    Inflamm Bowel Dis; 2016 Apr 18; 22(4):969-75. PubMed ID: 26954707
    [Abstract] [Full Text] [Related]

  • 34. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
    Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Coelho R, Tavares P, Soares J, Sousa AL, Carvalho D, Sousa P, da Silva JP, Meira T, Silva Ferreira F, Dias CC, Chowers Y, Ben-Horin S, Magro F, on behalf Portuguese IBD Study Group (GEDII).
    Therap Adv Gastroenterol; 2016 Nov 18; 9(6):781-794. PubMed ID: 27803733
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument.
    Cerutti H, Tesi G, Petrini F, Bandini T, Cartocci A, Ianniello A, Bogi A, Muzzi C, Brogi A.
    Pract Lab Med; 2024 Mar 18; 39():e00374. PubMed ID: 38463198
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M.
    Intern Med J; 2019 Apr 18; 49(4):513-518. PubMed ID: 30091273
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory.
    Keating PE, Hock BD, Chin PKL, O'Donnell JL, Barclay ML.
    Ther Drug Monit; 2024 Oct 01; 46(5):619-626. PubMed ID: 38648648
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.